Header Logo

Connection

MILIND JAVLE to Kaplan-Meier Estimate

Back to Details
This is a "connection" page, showing publications MILIND JAVLE has written about Kaplan-Meier Estimate.
MILIND JAVLE
Connection Strength
0.260
Kaplan-Meier Estimate
  1. Arterial enhancement pattern predicts survival in patients with resectable and unresectable intrahepatic cholangiocarcinoma. Surg Oncol. 2022 Mar; 40:101696.
    View in: PubMed
    Score: 0.026
  2. Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). Invest New Drugs. 2021 02; 39(1):182-192.
    View in: PubMed
    Score: 0.023
  3. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology. 2020 Apr; 20(3):501-504.
    View in: PubMed
    Score: 0.022
  4. Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. Radiother Oncol. 2019 04; 133:54-61.
    View in: PubMed
    Score: 0.021
  5. Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. J Transl Med. 2018 11 06; 16(1):300.
    View in: PubMed
    Score: 0.021
  6. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol. 2018 05; 3(5):337-348.
    View in: PubMed
    Score: 0.020
  7. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer. PLoS One. 2016; 11(6):e0156910.
    View in: PubMed
    Score: 0.018
  8. Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancer. Diagn Pathol. 2015 Aug 21; 10:148.
    View in: PubMed
    Score: 0.017
  9. Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. Acta Oncol. 2015 Jul; 54(7):971-8.
    View in: PubMed
    Score: 0.016
  10. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas. 2014 Apr; 43(3):343-9.
    View in: PubMed
    Score: 0.015
  11. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest. 2014 Apr; 124(4):1525-36.
    View in: PubMed
    Score: 0.015
  12. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Invest New Drugs. 2013 Oct; 31(5):1375-83.
    View in: PubMed
    Score: 0.014
  13. Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. Gastroenterology. 2010 Aug; 139(2):464-73, 473.e1-3.
    View in: PubMed
    Score: 0.011
  14. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs. 2011 Aug; 29(4):694-9.
    View in: PubMed
    Score: 0.011
  15. Reirradiation to the abdomen for gastrointestinal malignancies. Radiat Oncol. 2009 Nov 18; 4:55.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.